Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives

Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51

(2013) C. Michael Gibson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Heart Disease and Stroke Statistics—2013 Update

(2012) Alan S. Go et al.   CIRCULATION

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

(2011) J. Oldgren et al.   EUROPEAN HEART JOURNAL

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

(2011) John H. Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling

(2010) Terry N Flynn   Expert Review of Pharmacoeconomics & Outcomes Research

Estimating preferences for a dermatology consultation using Best-Worst Scaling: Comparison of various methods of analysis

(2008) Terry N Flynn et al.   BMC Medical Research Methodology

Thrombolytic Treatment for Stroke: Patient Preferences for Treatment, Information, and Involvement

(2008) Karsten Bruins Slot et al.   Journal of Stroke & Cerebrovascular Diseases

Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry

(2008) Keith AA Fox et al.   Nature clinical practice. Cardiovascular medicine